Lyudmila Bazhenova, MD
Dr. Lyudmila Bazhenova is a medical oncologist who practices at Moores Comprehensive Cancer Center at UC San Diego, in San Diego, California. She specializes in treating patients with all types of lung cancer and thoracic malignancies, including malignant pleural mesothelioma. She is also a clinical professor of Medicine at UC San Diego Medical School.[1]
Dr. Bazhenova works as part of a multidisciplinary team of surgical oncologists and radiation oncologists to ensure that patients receive the care that is best suited to their conditions and needs. To that end, she leads a weekly lung tumor board at which she and her colleagues confer on treatment options for the patients under their care.[1]
Education and Career
Dr. Bazhenova earned her medical degree at Nizhny Novgorod State Medical Academy in Russia. Following graduation, she completed an internship and residency in Internal Medicine at the VA Greater Los Angeles Healthcare System and a fellowship in Hematology and Oncology at Scripps Clinic Green Hospital.[1]
Research
Dr. Bazhenova’s research concentrates on lung cancer, particularly on lung cancer in women and non-smokers. She is an active participant in cooperative group clinical trials, often designing and implementing clinical investigations including phase II studies and correlative science projects with several UCSD investigators.[2]
Clinical Trials[2]
- Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial). Start Date: Apr 2021. Estimated Completion Date: Dec 2027. Recruitment Status: Recruiting. Condition(s): Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Carcinoma, Carcinoma, Lung Tumor
- CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC. Start Date: Mar 2021. Estimated Completion Date: Aug 2025. Recruitment Status: Recruiting. Condition(s): Lung Cancer, Non-Small Cell Lung Cancer, Lung Tumor
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial. Start Date: Jun 2020. Estimated Completion Date: Dec 2024. Recruitment Status: Recruiting. Condition(s): Non-Small Cell Lung Cancer, Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Cancer, Immunotherapy, Carcinoma, Lung Tumor, Squamous Cell Carcinoma
- Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation. Start Date: Apr 2019. Recruitment Status: Available, Condition(s): Lung Cancer, Non-Small Cell Lung Cancer, Thyroid Cancer, Colon Cancer, Colorectal Cancer, Breast Cancer, Pancreatic Cancer, Solid Tumor
Publications[2]
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3. J Clin Oncol. 2024 Feb 28; JCO2302744. Jaiyesimi IA, Leighl NB, Ismaila N, Alluri K, Florez N, Gadgeel S, Masters G, Schenk EL, Schneider BJ, Sequist L, Singh N, Bazhenova L, Blanchard E, Freeman-Daily J, Furuya N, Halmos B, Azar IH, Kuruvilla S, Mullane M, Naidoo J, Reuss JE, Spigel DR, Owen DH, Patel JD. PMID: 38417091.
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3. J Clin Oncol. 2024 Feb 28; JCO2302746. Jaiyesimi IA, Leighl NB, Ismaila N, Alluri K, Florez N, Gadgeel S, Masters G, Schenk EL, Schneider BJ, Sequist L, Singh N, Bazhenova L, Blanchard E, Freeman-Daily J, Furuya N, Halmos B, Azar IH, Kuruvilla S, Mullane M, Naidoo J, Reuss JE, Spigel DR, Owen DH, Patel JD. PMID: 38417098.
Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial. Clin Cancer Res. 2024 Jan 26. Parra ER, Zhang J, Duose DY, Gonzalez-Kozlova E, Redman MW, Chen H, Manyam GC, Kumar G, Zhang J, Song X, Lazcano R, Marques-Piubelli ML, Laberiano-Fernandez C, Rojas F, Zhang B, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Provencher J, Yu J, Cerami E, Moravec R, Kannan K, Luthra R, Alatrash G, Huang HH, Xie H, Patel M, Nie K, Harris J, Argueta K, Lindsay J, Biswas R, Van Nostrand S, Kim-Schulze S, Gray JE, Herbst R, Wistuba II, Gettinger S, Kelly K, Bazhenova L, Gnjatic S, Lee JJ, Zhang J, Haymaker C. PMID: 38277235.
Repotrectinib in a Patient With NTRK Fusion-Positive Pancreatic Carcinoma and Congenital Long QT Syndrome. JCO Precis Oncol. 2024 Jan; 8:e2300265. Yun KM, Narezkina A, Redfern C, Velasco K, Bazhenova L. PMID: 38271657.
ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study. Target Oncol. 2023 Jul; 18(4):571-583. Wang M, Slatter S, Sussell J, Lin CW, Ogale S, Datta D, Butte AJ, Bazhenova L, Rudrapatna VA. PMID: 37341856; PMCID: PMC10345061.
Corrigendum to “Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level”: [Annals of Oncology 34 (2023) 327-332]. Ann Oncol. 2023 Aug; 34(8):725-726. Bazhenova L. PMID: 37296057.
